CRI Genetics AI Market Strategy Report - DNA Testing Kits

Answer Capsule

CRI Genetics holds minimal recommendation-stage visibility in the DNA testing kits category, with valid recommendation coverage of just 0.33% in September 2026. The brand is present in only 0.98% of qualified AI observations, and it received no top-three placements across the entire benchmark. The clearest weakness is the absence of any recommendation conversion from the small mention base, while the clearest opportunity lies in building a public evidence layer that gives AI systems a reason to surface the brand in discovery prompts.

Who This Report Is For

This report is for marketing, brand, and growth leaders at CRI Genetics who need to understand why the brand is nearly invisible in AI-generated recommendations for DNA testing kits and what would be required to change that position.

Report Card

Executive Summary

CRI Genetics is effectively absent from AI-generated recommendations in the DNA testing kits category. The September 2026 LLM Authority Index benchmark shows the brand with a raw mention presence rate of 0.98%, meaning it appeared in just 6 of 614 qualified observations. Of those 6 mentions, only 2 qualified as valid recommendations, producing a valid recommendation coverage of 0.33%. The brand recorded zero top-three placements and zero rank-one placements across the entire benchmark.

The sentiment picture is modestly positive but built on a trivial sample. CRI Genetics recorded 2 positive mentions, 4 neutral mentions, and no negative mentions, producing a net sentiment score of 0.3333. The absence of negative framing is not a strategic asset at this scale; it simply reflects how rarely the brand surfaces in AI responses at all.

The strongest platform signal for CRI Genetics comes from Google AI Overviews, where the brand appeared in 1 observation and received its only rank-eligible recommendation. Google AI Mode contributed 5 mentions but no valid recommendation credit. ChatGPT, Copilot, Gemini, and Perplexity returned no CRI Genetics presence whatsoever in September 2026.

The clearest gap is structural. CRI Genetics is not being displaced by competitors in most prompts; it is simply not part of the consideration set that AI systems generate. The brands winning recommendation-stage visibility, AncestryDNA at 73.3% coverage and 23andMe at 65.1%, are being surfaced because the public evidence layer consistently supports them as category answers. CRI Genetics lacks that support.

What CRI Genetics Is Winning

The evidence base for CRI Genetics wins is narrow. The brand has no top-three placements, no rank-one placements, and no platform where it holds meaningful recommendation strength.

The only measurable positive is the absence of negative framing. CRI Genetics recorded zero negative mentions across all 614 qualified observations. Every mention of the brand was either positive or neutral. This suggests that when AI systems do reference CRI Genetics, they do not frame it negatively, but the sample is too small to treat this as a durable reputational signal.

The brand also received its single rank-eligible recommendation on Google AI Overviews, which is the only platform where CRI Genetics converted presence into any form of recommendation credit. That is a narrow pocket of evidence, not a strategic foothold.

Where CRI Genetics Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Which platforms show no CRI Genetics presence at all?
• How does CRI Genetics' absence from AI recommendation sets compare with category leaders like AncestryDNA and 23andMe?

The primary gap for CRI Genetics is total absence from the AI recommendation set. The brand is not losing top-three slots to competitors; it is not appearing in the candidate list that AI systems generate for DNA testing kit prompts.

Compare this to the category leaders. AncestryDNA appears in 99.5% of qualified observations and is recommended in 73.3% of them. 23andMe appears in 95.6% of observations and is recommended in 65.1%. Even mid-tier brands like FamilyTreeDNA, at 58.8% valid recommendation coverage, hold a position that CRI Genetics cannot approach with its current public evidence footprint.

The platform gap is equally stark. ChatGPT, Copilot, Gemini, and Perplexity returned no CRI Genetics mentions in September 2026. Google AI Mode mentioned the brand 5 times but did not recommend it. Only Google AI Overviews produced a single valid recommendation. A brand that is invisible across four of six tracked platforms has no meaningful AI discovery presence.

The competitive displacement story is indirect. When AI systems answer prompts like "best DNA test" or "best genetic testing kit," they consistently construct shortlists from AncestryDNA, 23andMe, MyHeritage DNA, and FamilyTreeDNA. CRI Genetics is not being compared and rejected; it is being omitted before comparison begins.

Biggest Opportunity

Questions This Section Answers

• What type of public evidence layer would give AI systems a reason to include CRI Genetics in DNA testing kit answers?

The clearest opportunity for CRI Genetics is to build a recommendation-ready public evidence layer that gives AI systems a defensible reason to include the brand in discovery answers.

The benchmark shows that AI systems in this category construct their recommendations from brands with strong, retrievable public footprints. The leaders are mentioned across nearly every prompt because their product attributes, comparisons, reviews, and category positioning are well represented in the sources AI systems draw from. CRI Genetics has none of that representation at scale.

The path forward is not to chase mention volume. It is to create the specific types of public content, comparison-ready pages, expert reviews, and category authority signals that AI systems can retrieve and synthesize when a buyer asks which DNA testing kit to choose. Until that evidence layer exists, CRI Genetics will remain outside the consideration set regardless of its actual product quality.

Competitive Landscape

Questions This Section Answers

• Where does CRI Genetics rank in AI recommendation strength relative to the tracked DNA testing kit brands?
• Which metrics in the competitive table should be read cautiously given CRI Genetics' small sample size?

AncestryDNA holds dominant recommendation-stage strength in the DNA testing kits category, with 23andMe as the strongest challenger. CRI Genetics sits at the bottom of the tracked competitive set with negligible recommendation coverage and no top-three presence.

Average recommended rank covers rank-eligible recommendations only.

The table shows CRI Genetics tied with Health Nucleus at the bottom of the competitive set, with no top-three placements and no rank-one placements. The brand's average recommended rank of 5.00 comes from a single rank-eligible recommendation, so it should not be read as a stable positioning signal. The sentiment score of 0.3333 is the second-lowest in the category, reflecting a mention base too small to carry strategic meaning.

Prompt Evidence

Google AI Overviews / Brand Recommendation Prompt: "What is the best DNA ancestry kit to buy?" Result: CRI Genetics received its only rank-eligible recommendation of the benchmark, appearing in a lower-list position behind the category leaders.

Google AI Mode / Brand Recommendation Prompt: "How do I check my ethnicity?" Result: CRI Genetics was mentioned in a small number of responses but received no valid recommendation credit, appearing as context rather than as a suggested option.

ChatGPT / Brand Recommendation Prompt: "Which DNA test is best for ancestry?" Result: CRI Genetics received no mention. ChatGPT constructed its answer from the category leaders without surfacing the brand.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map the specific prompts, platforms, and competitor responses where CRI Genetics is absent to identify which high-intent discovery questions offer the most realistic entry points.

Phase 2: Recommendation Readiness Plan Identify the product attributes, differentiators, and buyer questions where CRI Genetics can credibly compete, then define the messaging framework AI systems would need to retrieve.

Phase 3: Owned Answer Layer Buildout Develop comparison-ready pages and category-specific content that answer the discovery prompts where the brand currently has no presence.

Phase 4: Citation / Authority Layer Development Build the external citation footprint, expert reviews, and third-party references that give AI systems retrievable sources supporting CRI Genetics as a legitimate category option.

Phase 5: Monthly AI Visibility and Recommendation Tracking Measure changes in mention presence, valid recommendation coverage, and platform-level visibility to determine whether the evidence layer is shifting AI behavior.

Why This Matters

AI-generated recommendations are becoming the first filter in buyer consideration for DNA testing kits. When a prospective customer asks an AI assistant which kit to buy, the answer is being constructed from a small set of brands with strong public evidence layers. CRI Genetics is not part of that set.

Presence alone would not solve the problem. The benchmark shows that being mentioned is not the same as being recommended. CRI Genetics needs both visibility and the specific type of public evidence that causes AI systems to include the brand in a shortlist. The next move is to build the prompt, page, and citation layers that make the brand retrievable, relevant, and recommendable at the moment of discovery.

Core Metrics

Sentiment Score

Questions This Section Answers

• How is CRI Genetics' net sentiment score of 0.3333 calculated?
• Why should a small-sample sentiment score be treated as directional rather than conclusive?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For CRI Genetics, the calculation is (2 × 1 + 4 × 0 + 0 × -1) / 6, producing a net sentiment score of 0.3333.

This score matters because unclassified mention counts are misleading. A brand that appears in 6 responses could be framed positively, negatively, or neutrally, and those frames carry very different commercial meaning. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, and at this sample size even the classification should be treated as directional rather than conclusive.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of CRI Genetics' AI recommendation visibility in the DNA testing kits category, not a client implementation case study.
2. The reporting window is September 2026, with comparative context drawn from the July 2026 and August 2026 benchmark series.
3. Six AI/search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, Google AI Mode, and Google AI Overviews.
4. The benchmark began with 800 source prompt-surface observations and produced 614 qualified observations after relevance and qualification filtering.
5. The competitor universe includes 10 tracked brands: AncestryDNA, 23andMe, MyHeritage DNA, FamilyTreeDNA, Nebula Genomics, Living DNA, African Ancestry, tellmeGen, CRI Genetics, and Health Nucleus.
6. All qualified observations fell into the Brand Recommendation buyer-intent class, representing discovery and consideration prompts. No qualified observations were captured in pricing or multi-brand comparison classes.
7. Stage 0 extraction retained prompt-level data including query, platform, answer, brand outcome, recommendation placement, and sentiment classification.
8. A mention is defined as any appearance of the brand in a qualified AI response, regardless of framing or recommendation status.
9. A valid recommendation requires the brand to be positively recommended or shortlisted in the response, not merely referenced or listed as context.
10. Brand-level percentages use the 614 qualified observations as the public denominator, not the 800 raw prompts collected.
11. Small-count caution applies: CRI Genetics recorded only 6 mentions and 2 valid recommendations, so percentage movements can shift meaningfully with a change of just a few prompts.
12. The benchmark records changes in AI recommendation behavior; it does not by itself establish why those changes occurred.

See How AI Is Recommending Your Brand

The public benchmark shows where CRI Genetics stands in AI-generated recommendations, but it does not explain which prompts, platforms, and evidence sources would need to change to move the brand into the consideration set. A company-level AI visibility audit maps those patterns into a prioritized strategy, turning the benchmark's current position into a concrete path toward recommendation readiness.